Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
511819
Reference Type
Journal Article
Title
Advances in nuclear magnetic resonance for drug discovery
Author(s)
Powers, R
Year
2009
Volume
4
Issue
10
Page Numbers
1077-1098
Language
English
DOI
10.1517/17460440903232623
Abstract
Background: Drug discovery is a complex and unpredictable endeavor with a high failure rate. Current trends in the pharmaceutical industry have exacerbated these challenges and are contributing to the dramatic decline in productivity observed over the last decade. The industrialization of science by forcing the drug discovery process to adhere to assembly-line protocols is imposing unnecessary restrictions, such as short project timelines. Recent advances in NMR are responding to these self-imposed limitations and are providing opportunities to increase the success rate of drug discovery. Objective/method: A review of recent advancements in NMR technology that have the potential of significantly impacting and benefiting the drug discovery process is presented. These include fast NMR data collection protocols and high-throughput protein structure determination, rapid protein-ligand co-structure determination, lead discovery using fragment-based NMR affinity screens, NMR metabolomics to monitor in vivo efficacy and toxicity for lead compounds, and the identification of new therapeutic targets through the functional annotation of proteins by functional annotation screening technology using NMR. Conclusion: NMR is a critical component of the drug discovery process, where the versatility of the technique enables it to continually expand and evolve its role. NMR is expected to maintain this growth over the next decade with advancements in automation, speed of structure calculation, in-cell imaging techniques and the expansion of NMR amenable targets.
Keywords
drug discovery; fragment-based screening; metabolomics; NMR; structural; biology; protein-structure determination; structure-based design; principal; component analysis; chemical-shift assignments; residual dipolar; couplings; automated noe assignment; x-ray crystallography; cell-free; synthesis; malate synthase-g; nmr data sets
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity